Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375017 | 1.00 | ALDH1A1 (0.35) | ALDH1A1FFAR3TDP1TSHRKDM4E | |
| SCHEMBL6871163 | 0.82 | ALDH1A1 (0.33) | ALDH1A1FFAR3TDP1TSHRKDM4E | |
| SCHEMBL5595771 | 0.81 | FFAR3 (0.35) | ALDH1A1FFAR3TSHRKDM4EGRIK1 | |
| SCHEMBL18169351 | 0.81 | FFAR3 (0.35) | ALDH1A1FFAR3TSHRKDM4EGRIK1 | |
| SCHEMBL20109820 | 0.80 | ALDH1A1 (0.38) | ALDH1A1FFAR3TDP1TSHRKDM4E | |
| SCHEMBL1977289 | 0.80 | ALDH1A1 (0.38) | ALDH1A1FFAR3TDP1TSHRKDM4E | |
| SCHEMBL4273874 | 0.79 | TSHR (0.33) | ALDH1A1FFAR3TSHRKDM4EABAT | |
| SCHEMBL2308752 | 0.79 | TSHR (0.33) | ALDH1A1FFAR3TSHRKDM4EGRIK1 | |
| SCHEMBL29373734 | 0.79 | TSHR (0.33) | ALDH1A1FFAR3TSHRKDM4EGRIK1 | |
| SCHEMBL28183840 | 0.79 | KDM4E (0.43) | TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | claimed |
| US-7622612-B2 | Tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2009-11-24 | — | — | US | disclosed |
| US-20070021427-A1 | Novel tricyclic derivatives and their use | CHEMTECH RESEARCH INCORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021427-A1 | Novel tricyclic derivatives and their use | NFATC1, IL2, CCL2 | ALDH1A1 2078/4885FFAR3 3784/4885TDP1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.